Nuvectis Pharma has transformed from a single-drug oncology company into a rare-disease player by licensing worldwide rights (outside China) to NXP100, an oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), and NXP200, an oncology asset, from Haisco Pharmaceutical Group. NXP100 showed strong Phase 3 results, outperforming the standard infused drug eculizumab with a 59.5% transfusion-free normal hemoglobin response versus 8.3%. Regulatory approval decisions in China are expected within 6 to 12 months, targeting late 2026 or early 2027. This move positions Nuvectis in a fast-growing market, with the global PNH treatment market projected to nearly double by 2030, and adds multiple near-term catalysts including upcoming oncology data and regulatory reviews.
Vicor is rated as a 'Buy' with a price target of $846 per share by 2033, driven by its advanced Vertical Power Delivery (VPD) technology that aligns with next-gen AI data center needs. The company aims to nearly quintuple its revenue from $470 millio...
Southwest Airlines is rated a buy with an expected 15-20% upside driven by a commercial overhaul that has led to record unit revenue growth and a resilient profit mix. The airline's transformation into a merchandised model with new fare structures an...
Walhalla Gold Corp. has appointed Owen Greenberger as Vice-President of Exploration to enhance its exploration efforts across its Victorian precious and critical minerals portfolio. Greenberger brings nearly 20 years of Australian exploration experie...
NEAR Protocol's token price surged about 80% in seven days, reaching $4.29, driven by Bitcoin's rally past $86,000 and strong institutional interest. The NEAR Intents platform saw $29.3 billion in cumulative transaction volume and over $200 million i...
Kingfisher PLC shares rose as much as 10.6% following a strong first-half profit performance driven by improved margins. The company upgraded its annual profit forecast to £595-635 million, up from £565-625 million, and raised free cash flow guidance...
